邁克生物(300463.SZ):終止實施2024年限制性股票激勵計劃
格隆匯6月11日丨邁克生物(300463.SZ)公佈,鑑於公司經營所面臨的內外部環境與公司制定2024年限制性股票激勵計劃時相比發生較大變化,本激勵計劃原設定的業績考核指標已無法客觀反映當前實際經營態勢,繼續實施2024年限制性股票激勵計劃難以充分實現激勵計劃的設計目的和效果。為充分落實對員工的有效激勵,保障廣大投資者的合法權益,綜合考慮市場環境因素並結合公司自身實際經營情況、未來發展規劃等,公司經審慎研究論證後決定終止實施本激勵計劃,回購註銷已授予尚未解鎖的全部384.4966萬股第一類限制性股票,並作廢已授予尚未歸屬的全部345.7934萬股第二類限制性股票,與本激勵計劃配套的《2024年限制性股票激勵計劃(草案)》《2024年限制性股票激勵計劃實施考核管理辦法》等文件一併終止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.